SinoMab BioScience AAQS 2024

Čo robí SinoMab BioScience?

SinoMab BioScience Ltd is a Chinese biotechnology company specializing in the research, development, and commercial production of innovative biopharmaceutical products. The company was founded in 2001 and is based in Hong Kong. The company's business model focuses on the development of antibody-based therapies for the treatment of cancer and inflammatory diseases. SinoMab BioScience Ltd collaborates closely with leading biopharmaceutical companies, academic institutions, and research facilities worldwide to develop therapeutics that have the potential to improve patients' lives. The company operates in various sectors, including research and development, production, and distribution of biopharmaceutical products. SinoMab also has its own research and development department dedicated to the discovery and development of antibodies. The company aims to build a pipeline of innovative products that address a wide range of medical needs. Currently, SinoMab BioScience Ltd has a range of product candidates in clinical development targeting the treatment of cancer and inflammatory diseases. One of the key products is the antibody preparation SMM-114, used for the treatment of patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma and represents one of the most common cancers in adults. SMM-114 actively inhibits the proliferation of tumor cells by blocking the protein CXCR4, which is expressed on the surface of cancer cells. Another important product candidate of the company is SMAB022, a monoclonal antibody for the treatment of patients with cutaneous squamous cell carcinoma. This product binds to the Epidermal Growth Factor Receptor (EGFR) protein on the surface of cancer cells and inhibits their proliferation. SinoMab BioScience Ltd also has a manufacturing and distribution department for biopharmaceutical products. The company has a GMP-compliant production facility and offers services such as process development, production and purification procedures, stabilization, and formulation of biopharmaceuticals. In addition, SinoMab BioScience Ltd has developed its own in vitro diagnostic (IVD) test for the detection of human papillomavirus (HPV). This disease is one of the most common sexually transmitted infections and is a serious health problem. The HPV IVD is an innovative test system that enables rapid, accurate, and reliable identification of HPV infections. Research and development is highly valued by the company, and it has established its own R&D department consisting of experienced scientists and engineers. This department focuses on the discovery and development of novel biopharmaceutical products and collaborates closely with academic institutions and research facilities. Furthermore, SinoMab BioScience Ltd has formed partnerships with other leading biopharmaceutical companies to collaborate in exploring and harnessing the potential of antibodies for the treatment of diseases. In conclusion, SinoMab BioScience Ltd is an innovative biotechnology company specializing in the development of novel biopharmaceutical therapies for the treatment of cancer and inflammatory diseases. The company has a strong research and development expertise and has built a pipeline of product candidates with the potential to improve patients' lives. With its wide range of products and services in the manufacturing and distribution of biopharmaceuticals, SinoMab BioScience Ltd has established a strong position in the market. SinoMab BioScience ist eines der beliebtesten Unternehmen auf Eulerpool.com.